InMode Q4 Preliminary Revenue Rises

InMode (INMD) provided preliminary Q4 revenue of $103.6m–$103.8m versus $97.9m in Q4 2024, but issued full-year fiscal 2025 revenue guidance of $370.2m–$370.4m, down from prior-year revenue of $394.8m (≈6.2% decline). Fiscal 2026 revenue is guided at $365m–$375m. The mixed signal—quarterly strength but lower full-year guidance—could pressure near-term sentiment ahead of the company’s Q4 and FY2025 results due Feb. 10; shares last closed at $15.64 (+0.52%).

Analysis

Market structure: INMD's guidance implies a modest near-term reshuffling within aesthetic devices — Q4 revs ~ $103.7M (+6% y/y) masks a FY25 revenue downgrade to ~$370.3M from $394.8M (~-6.2% y/y), signaling weaker procedure volumes or dealer capex pause. Direct losers are high-end elective procedure device vendors and independent clinic operators; winners are larger diversified medtech (IHI constituents) with less cosmetic exposure and service/consumable-focused businesses that capture recurring revenue. Cross-asset: a softer INMD outlook is slightly risk-positive for rates (minor upward duration bids) and should raise implied equity options vol for INMD near Feb-10 earnings.

Risk assessment: Immediate risk is an earnings disappointment / guide cut on Feb 10 that surprises on procedure volumes; medium-term (3–12 months) risks include consumer spending decline and clinic capital deferment; tail risks include FDA safety actions or large warranty/recall charges that could cut revenues >20% and compress multiples. Hidden dependencies: equipment attach rates, international distributor health, and clinic financing lines obscure true demand timing; catalysts are Feb 10 release, trade-show order flow data, and macro consumer confidence prints (U.S. mfg/retail data over next 60 days).

Trade implications: Direct play — tactical bearish position: size ~2–3% NAV via a 3–6 month put vertical (e.g., buy 3-mo 16/12 put spread) to limit downside risk ahead of Feb 10; if earnings confirm stabilization, close for profit. Pair trade — long diversified medtech (IHI ETF, 2–3% weight) vs short INMD (1–2%) to express secular resilience. Options: consider buying Jan–Mar straddle only if implied vol cheap after a pullback; otherwise prefer directional spreads. Rotate modestly from pure-aesthetics names into service/consumable-heavy healthcare names (IHI, CDMO suppliers) over 1–3 months.

Contrarian angles: Consensus focuses on volume weakness but may underweight margins — if INMD sustains gross margins through higher-margin consumables/therapy introductions, FY26 guide of $365–375M could be conservative, creating a mean-reversion buy. Market may overshoot on Feb 10 negative commentary; a tactical long if price < $13 with a 6–12 month horizon captures mispricing or M&A interest (INMD's tech makes it a plausible strategic acquisition target). Watch clinic capex financing availability as the largest second-order signal of sustained demand.

Key Decisions for Investors

• Establish a tactical bearish position in INMD sized 2–3% of NAV via a 3-month put vertical (example: buy 16 / sell 12 puts) to hedge event risk into the Feb 10 earnings release and cap downside to defined loss.
• Initiate a relative-value pair: long IHI ETF (2–3% NAV) and short INMD (1–2% NAV) to express a rotation from niche aesthetic devices into diversified medical devices over the next 3–6 months.
• Set a conditional opportunistic long: accumulate INMD up to 2–3% NAV only if share price drops below $13 or if Feb 10 results show revenue within guided range but stable/improving gross margins; target 30–50% upside within 6–12 months or exit if margins deteriorate.
• Monitor within 30 days: clinic financing spreads, U.S. consumer confidence and two-week trends in search/booking data for aesthetic procedures; if these deteriorate >10% sequentially, increase short exposure by 50%.